DABUR INDIA LTD Result Update (CONSOLIDATED BASIS): Q3 FY19

DABUR INDIA LTD Result Update (CONSOLIDATED BASIS): Q3 FY19 Index Details Stock Data Sector Personal Products BSE Code 500096 Face Value 1.00 52wk. High / Low (Rs.) 490.70/312.45 Volume (2wk. Avg.) 203000 Market Cap (Rs. in mn.) 798014.34 Annual Estimated Results(A*: Actual / E*: Estimated) Years(Rs in mn) FY18A FY19E FY20E Net Sales 77483.40 86700.46 94503.50 EBITDA 19226.20 20777.48 22864.92 Net Profit 13722.80 14770.65 16280.83 EPS 7.79 8.36 9.22 P/E 57.99 54.03 49.02 Shareholding Pattern (%) As on Dec 2018 As on Sep 2018 Promoter 67.89 67.88 Public 32.11 32.12 Others -- -- 1 Year Comparative Graph DABUR INDIA LTD S&P BSE SENSEX CMP: 451.80 FEB 2 nd, 2019 Overweight SYNOPSIS ISIN:INE016A01026 Dabur India Limited is one of the worlds largest Ayurvedic and Natural Health Care Company. Consolidated net profit registered a growth of 10.26% and stood at Rs. 3672.10 mn in the current quarter as against Rs. 3330.30 mn in the corresponding period of the previous year. Consolidated revenue for the 3 rd quarter stood at Rs. 21992.10 mn from Rs. 19664.40 mn in the corresponding period of the previous year, up by 11.84%. During Q3 FY19, consolidated EBIDTA was Rs. 5206.40 mn as against Rs. 4698.10 mn in the corresponding period of the previous year. Consolidated PBT of the company for Q3 FY19 registered a growth of 10.31% at Rs. 4590.50 mn as against Rs. 4161.50 mn in the Q3 FY18. Revenue of the company registered at Rs. 64048.60 mn in 9M FY19 as against Rs. 57154.30 mn in 9M FY18, up by 12.06%. During 9M FY19, PAT rose by 11.89% at Rs. 10747.30 mn as compared to Rs. 9605.60 mn in 9M FY18. Domestic business revenue grew by 15.2% led by volume growth of 12.4% Growth in International Business was impacted by continued under performance of MENA markets and adverse currency movement. Contribution of Domestic FMCG increased to 72.2% from 70.2% last year. International Business contributed 25.0% as compared to 27.1% last year. Net Sales and PAT of the company are expected to grow at a CAGR of 7% and 8% over 2017 to 2020E, respectively. PEER GROUPS CMP MARKET CAP EPS(TTM) P/E(X)(TTM) P/BV(X) DIVIDEND Company Name (Rs.) Rs. In mn. (Rs.) Ratio Ratio (%) Dabur India Ltd 451.80 798014.34 8.34 54.17 13.95 750.00 Hindustan Unilever Ltd 1796.25 3888250.70 27.02 66.48 54.95 2000.00 Godrej Consumer Products Ltd 714.35 730184.40 19.80 36.08 11.67 1200.00 Marico Ltd 376.20 485623.20 6.75 55.73 19.00 425.00

QUARTERLY HIGHLIGHTS (CONSOLIDATED BASIS) Results updates- Q3 FY19, (Rs in millions) Dec-18 Dec-17 % Change Revenue 21992.10 19664.40 11.84% Net Profit 3672.10 3330.30 10.26% EPS 2.08 1.89 9.96% PBIDT 5206.40 4698.10 10.82% The consolidated net profit registered a growth of 10.26% and stood at Rs. 3672.10 million in the current quarter as against Rs. 3330.30 million in the corresponding period of the previous year. Revenue for the 3 rd quarter stood at Rs. 21992.10 million from Rs. 19664.40 million, up by 11.84% when compared with the prior year period. Reported earnings per share of the company stood at Rs. 2.08 a share in the third quarter as compared to Rs. 1.89 per share in the corresponding previous quarter. Profit before interest, depreciation and tax is Rs. 5206.40 million as against Rs. 4698.10 million in the corresponding period of the previous year, up by 10.82%. Break up of Expenditure Break up of Expenditure Cost of Materials Consumed ( include Excise Duty) Purchase of Stock in Trade Employee Benefits Expense Depreciation & Amortization Expense Advertisement and Publicity Q3 FY19 Value in Rs. Million Q3 FY18 % Change 8447.80 8049.00 5% 1981.40 2397.80-17% 2375.90 2048.30 16% 448.50 404.50 11% 1780.70 1853.20-4% Others 2228.70 2204.70 1%

Segment Revenue: Q3 FY19 Overview: Domestic business revenue grew by 15.2% led by volume growth of 12.4% Growth in International Business was impacted by continued under performance of MENA markets and adverse currency movement. Contribution of Domestic FMCG increased to 72.2% from 70.2% last year International Business contributed 25.0% as compared to 27.1% last year Domestic FMCG Category-wise Sales: Category Highlights: Home and Personal Care (HPC) Q3 FY19: HPC posted growth of 16.3% in Q3 FY19 Oral care recorded growth of 10.0% with toothpastes growing at 11.1% Red Toothpaste Franchise continued its growth momentum with RTP growing by 22.6%

Babool was impacted by high competitive intensity at economy price points Hair oil category grew by 23.6% with all round growth in all brands and gain in market share Shampoos category reported strong growth of 25.2% led by on ground activations and visibility drive Homecare category posted growth of 8.9% with strong growth in Sanifresh Skin care recorded growth of 19.3% driven by strong double digit growth in Gulabari and good performance of bleach portfolio Healthcare (HC) Q3 FY19: Healthcare grew by 15.9% in Q3 FY19 Health Supplements recorded growth of 13.8% on the back of double digit growth in Chyawanprash and Honey Chyawanprash grew by 10.0% Dabur Honey grew by 19.8% Digestives posted growth of 22.5% driven by continued strong performance of Hajmola tablets and Pudin Hara OTC category grew by 17.7% on the back of good growth in Lal Tail, Honitus and Shilajit Ethicals portfolio grew by 17.4% driven by strong growth across product categories Foods Q3 FY19: Beverages grew by 11.5% Ethnic Masala range performed well launch in MT showing good traction; being rolled out to GT Activ Coconut Water continues on its strong growth trajectory New variants of juices to be launched in coming season Market share at peak level of around 56% a gain of ~300 bps over the same quarter last year Latest Launches: The company launched Soya-Protein enriched Almond Hair Oil in Q3 FY19. The company launched Gulabari Soft and Rosy in Q3 FY19. The company launched Dabur Chyawanprash Sugarfree for Diabetic Persons. The company launched various recepie pastes under name Homemade. The company launched Brahmi Amla Oil in 40 ml Bottle. The company lauched Honitus Madhvani paste which is specific for Caugh and Cold People. The company also lauched Dabur Chyawanprash which is for Immunity for all.

International Business Q3 FY19: International Business reported 3.4% growth with constant currency growth of around 1% Egypt business was under pressure on account of hyper inflation and liquidity issues SAARC grew by 11% on the back of strong growth in Pakistan and Bangladesh Hobby had a strong quarter, growing by 31% in constant currency terms; however currency devaluation impacted in translation GCC markets declined by 12% due to consumption pressure and sharp decline in categories Namaste business reported double digit growth in SSA & North America but was brought down by EU & Middle East. COMPANY PROFILE Dabur India Limited is one of India's leading FMCG Companies. Building on a legacy of quality and experience for 135 years, Dabur is today India's most trusted name and one of the world's largest Ayurvedic and Natural Health Care Company. Dabur India's FMCG portfolio today includes five flagship brands with distinct brand identities - Dabur as the master brand for natural healthcare products, Vatika for premium personal care, Hajmola for digestives. Real for fruitbased beverages, and Fern for fairness bleaches & skin care.

FINANCIAL HIGHLIGHT (CONSOLIDATED BASIS) Balance Sheet as of March 31, 2017-2020E (A*- Actual, E* -Estimations & Rs. In Millions) FY17A FY18A FY19E FY20E ASSETS Non-Current Assets a) Property, plant and Equipment 14790.20 15521.00 16607.47 17603.92 b) Capital Work in Progress 421.00 415.10 435.86 462.01 c) Investment Property 549.90 541.60 563.26 591.43 d) Goodwill 4105.30 4115.40 4362.32 4580.44 e) Other Intangible Assets 138.60 103.10 87.64 78.87 f) Financial Assets i) Investments 24994.10 30917.80 37101.36 44150.62 ii) Loans 118.60 131.40 107.75 91.59 iii) Others 63.80 41.10 33.70 28.65 g) Non-Current Tax Assets 33.10 33.30 34.97 36.36 h) Other Non-Current Assets 963.10 799.00 878.90 949.21 1. Sub - Total Non- Current Assets 46177.70 52618.80 60213.22 68573.09 Current Assets a) Inventories 11067.10 12561.80 13817.98 14923.42 b) Financial Assets i) Investments 7407.50 7133.90 6919.88 6781.49 ii) Trade Receivables 6504.20 7060.80 7625.66 8311.97 iii) Cash and Cash Equivalents 1632.20 1538.00 1461.10 1417.27 iv) Bank Balance other than Cash Equivalents 1415.90 1522.60 1629.18 1726.93 v) Loans 38.00 348.80 551.10 870.74 vi) Others 381.20 282.70 231.81 190.09 c) Current Tax Assets (Net) 0.00 19.60 20.58 21.40 d) Other Current Assets 2698.60 3910.10 5004.93 6256.16 e) Assets Held for Sale 0.00 19.20 20.16 0.00 2. Sub - Total Current Assets 31144.70 34397.50 37282.40 40499.47 Total Assets (1+2) 77322.40 87016.30 97495.62 109072.56 EQUITY AND LIABILITIES EQUITY a) Equity Share Capital 1761.50 1761.50 1761.50 1761.50 b) Other Equity 46712.40 55303.70 64152.29 73775.14 c) Non-Controlling Interest 247.70 265.30 278.57 289.71 1. Total Equity 48721.60 57330.50 66192.36 75826.34 Non Current Liabilities a) Financial Liabilities i) Borrowings 4703.90 3643.40 3279.06 3016.74 ii) Other Financial Liabilities 37.10 42.50 46.75 49.09 b) Provisions 534.00 565.00 593.25 616.98 c) Deferred Tax Liabilities (Net) 1080.40 1090.50 1145.03 1190.83 2. Sub - Total Non Current Liabilities 6355.40 5341.40 5064.09 4873.63 Current Liabilities a) Financial Liabilities i) Borrowings 4403.30 4644.90 4784.25 4975.62 ii) Trade Payables 13100.30 14103.20 14827.50 15635.40 iii) Other Financial Liabilities 1746.90 2382.00 3144.24 4087.51 b) Other Current Liabilities 1691.00 1730.30 1816.82 1871.32 c) Provisions 918.90 1074.70 1235.91 1359.50 d) Current Tax Liabilities (Net) 385.00 409.30 425.67 438.44 3. Sub - Total Current Liabilities 22245.40 24344.40 26234.38 28367.79 Total Equity and Liabilities (1+2+3) 77322.40 87016.30 97495.62 109072.56

Annual Profit & Loss Statement for the period of 2017 to 2020E Value(Rs.in.mn) FY17A FY18A FY19E FY20E Description 12m 12m 12m 12m Net Sales 77014.40 77483.40 86700.46 94503.50 Other Income 2983.50 3051.80 3015.98 3227.09 Total Income 79997.90 80535.20 89716.44 97730.60 Expenditure -61925.00-61309.00-68938.96-74865.68 Operating Profit 18072.90 19226.20 20777.48 22864.92 Interest -540.30-530.50-647.57-725.28 Gross Profit 17532.60 18695.70 20129.91 22139.64 Depreciation -1428.60-1621.80-1782.21-1978.25 Profit Before Tax 16104.00 17073.90 18347.70 20161.39 Tax -3303.40-3353.50-3591.05-3893.16 Profit After Tax 12800.60 13720.40 14756.65 16268.23 Share of Profit & Loss Assoc 2.50 2.40 14.00 12.60 Net Profit 12803.10 13722.80 14770.65 16280.83 Equity Capital 1761.50 1761.50 1766.30 1766.30 Reserves 46712.40 55303.70 64152.29 73775.14 Face value 1.00 1.00 1.00 1.00 EPS 7.27 7.79 8.36 9.22 Quarterly Profit & Loss Statement for the period of 30 th June, 2018 to 31 st Mar, 2019E Value(Rs.in.mn) 30-June-18 30-Sep-18 31-Dec-18 31-Mar-19E Description 3m 3m 3m 3m Net sales 20806.80 21249.70 21992.10 22651.86 Other Income 736.50 812.10 752.50 714.88 Total Income 21543.30 22061.80 22744.60 23366.74 Expenditure -16945.60-16741.40-17538.20-17713.76 Operating profit 4597.70 5320.40 5206.40 5652.98 Interest -148.80-155.60-167.40-175.77 Gross profit 4448.90 5164.80 5039.00 5477.21 Depreciation -427.30-431.00-448.50-475.41 Profit Before Tax 4021.60 4733.80 4590.50 5001.80 Tax -723.80-961.30-923.60-982.35 Profit After Tax 3297.80 3772.50 3666.90 4019.45 Share of Profit & Loss of Assoc 2.20 2.70 5.20 3.90 Net Profit 3300.00 3775.20 3672.10 4023.35 Equity Capital 1766.30 1766.30 1766.30 1766.30 Face Value 1.00 1.00 1.00 1.00 EPS 1.87 2.14 2.08 2.28

Ratio Analysis Particulars FY17A FY18A FY19E FY20E EPS (Rs.) 7.27 7.79 8.36 9.22 EBITDA Margin (%) 23.47% 24.81% 23.96% 24.19% PBT Margin (%) 20.91% 22.04% 21.16% 21.33% PAT Margin (%) 16.62% 17.71% 17.02% 17.21% P/E Ratio (x) 62.16 57.99 54.03 49.02 ROE (%) 26.41% 24.04% 22.39% 21.54% ROCE (%) 28.91% 26.94% 25.68% 25.00% Debt Equity Ratio 0.19 0.15 0.12 0.11 EV/EBITDA (x) 43.96 41.29 38.31 34.82 Book Value (Rs.) 27.52 32.40 37.32 42.77 P/BV 16.42 13.95 12.11 10.56 Charts

OUTLOOK AND CONCLUSION At the current market price of Rs. 451.80, the stock P/E ratio is at 54.03 x FY19E and 49.02 x FY20E respectively. Earning per share (EPS) of the company for the earnings for FY19E and FY20E are seen at Rs. 8.36 and Rs. 9.22, respectively. Net Sales and PAT of the company are expected to grow at a CAGR of 7% and 8% over 2017 to 2020E, respectively. On the basis of EV/EBITDA, the stock trades at 38.31 x for FY19E and 34.82 x for FY20E. Price to Book Value of the stock is expected to be at 12.11 x and 10.56 x for FY19E and FY20E respectively. Hence, we say that, we are Overweight in this particular scrip for Medium to Long term investment. INDUSTRY OVERVIEW Fast moving consumer goods (FMCG) is the 4th largest sector in the Indian economy. There are three main segments in the sector Food and Beverages, Healthcare and Household and Personal Care. The FMCG sector has grown from $31.6 billion in 2011 to $49 billion in 2016, according to India Brand Equity Foundation (IBEF) report on the FMCG industry. Growing incomes, favourable demographics, easier access and changing lifestyles are the key growth drivers for the consumer market. The FMCG industry is expected to reap the benefits of the government s renewed focus on agriculture, education, healthcare, infrastructure and employment in its Union Budget 2018-19. These initiatives are expected to increase the disposable income in the hands of the common man, especially in the rural areas, which will be beneficial for the sector. The recent years have seen the emergence of a significant trend in the Indian consumer market: growing preference for herbal and Ayurvedic products. The herbal or natural wave has been gaining traction in India, driven by resurgent pride among the youth on Indian culture and Indian products. They have been showing greater willingness to embrace products

that offer the tried-and-tested benefits of traditional Ayurveda, but presented in modern day and contemporary formats. This trend has been gaining traction across the categories with leading MNCs also joining the bandwagon. Companies with traditional herbal positioning and strong R&D are more likely to benefit disproportionately from this trend. As the leading player in the Ayurveda and natural health and personal care market, Dabur has been working towards making traditional Indian knowledge available in a form that appeals to the modern consumer. India FMCG Business: The India FMCG business includes the Consumer Care Business comprising key categories like Health Care (encompassing Health Supplements, Digestives, OTC and Ethicals), Home & Personal Care (comprising Hair Care, Oral Care, Skin Care and Home Care) and Foods. The company has a wide distribution network, covering over 6.3 million retail outlets with a high penetration in both urban and rural markets. The India FMCG business, despite the strong headwinds in the form of pre-gst jitters reported 8.1% growth during fiscal 2017-18. Health Care: Ayurveda-based products have been gaining traction in India over the past few years on account of rising awareness about harmful effects of chemicals and allopathic medicines, coupled with increasing number of product innovations by companies. The pace of growth is expected to continue in years to come with a growing number of young people beginning to embrace this traditional medicine. According to a TechSci Research report, India Ayurvedic Products Market Forecast & Opportunities, 2011-2021, the Ayurvedic products market in India is projected to register a CAGR of 16% between 2016 and 2021. It says that the rising health concerns and awareness of side-effects of allopathy are some of the major factors driving consumer preference for Ayurvedic products in the country. The Government has also been making concerted efforts towards encouraging and promoting usage of Ayurvedic products through education and national awareness programmes. Various initiatives like celebration of the National Ayurveda Day, seminars, conclaves and programmes for prevention and control of Diabetes and Non-Communicable Diseases has increased awareness about this system of medicine among people. As the country s leading Science-based Ayurveda expert, Dabur has been at the forefront on carrying out collaborative research and modern technology to further establish the benefits of various traditional Ayurvedic formulations, products and ingredients. The Company constantly investing in not just updating and upgrading its Health Care portfolio, but also towards making it more contemporary and in sync with the ever-changing needs and aspirations of the modernday consumer. All this is being done while keeping the core of Ayurveda intact. The Dabur Research & Development Centre (DRDC) has been undertaking, coordinating and promoting research on scientific lines in Ayurvedic Sciences. This research work is executed by an able team of over 100 scientists and also through collaborative studies with various universities, hospitals, research institutes and government bodies. Dabur s Health Care vertical today comprises Health Supplements, Digestives, Over-The-Counter (OTC) and Ayurvedic Ethical products. This vertical contributed 31.7% to the India FMCG sales in 2017-18.

Home & Personal Care: Led by a widespread lifestyle shift, triggered mainly by environmental awareness, millennial trends and growing awareness about health and wellness, many of today s consumers are demanding natural or nature-based products in categories such as personal care, household care and cosmetics. A survey carried out by Euro monitor International reveals that over half of Indian consumers reported that natural or organic features are known to influence their hair and skin care purchase decisions. About 71% of consumers surveyed said that they would pick up a face cream or lotion provided it claimed to be natural, while 38% said they would buy a shampoo or hair oil, if it was made with botanical ingredients. These points towards a growing across-the-board trend among Indian consumers for natural ingredients in personal care products and an affinity and innate belief in the goodness of ancient Indian wisdom. For over a century, Dabur has been offering consumers natural and Ayurveda-based personal care solutions. Dabur offers a range of product covering Hair Care, Oral Care, Skin Care & Salon and Home Care. This vertical contributed 50.4% to the India FMCG sales. Foods: Dabur s Foods business largely comprises packaged fruit juices & beverages with culinary pastes forming a small part of the business. This business contributed 18.0% to the India FMCG Business. This business reported moderate growth during 2017-18 as the category witnessed increased competitive intensity and increase in number of players at the economy end of the market. Dabur is the pioneer in packaged fruit juice market in India and enjoys nearly 55% share of the category with a range of products under the brands Real and Real Activ. With the widest and healthiest product range in the industry, constant innovation and unwavering focus on quality, Dabur has maintained its lead despite the entry of new players offering lower priced and discounted products. The company increased its media spends and focused on enhancing its distribution footprint and penetration. During the festive season, Real introduced an exclusive range of 13 specially crafted gift packs of Real fruit beverages, offering consumers the option of gifting real health to their near and dear ones. The range has been eloquently designed to communicate the goodness of fruits and the concept of Festive Wishes of Good Health. Special utility pack options were also part of the offering, keeping up with the theme of offering consumers new, healthy gifting options. These packs were well received by consumers. Gift packs of Real fruit juices are also available during other festive seasons such as Rakhi, Eid and Christmas. As part of its theme of offering Health and Wellness the division had launched Active Coconut Water couple of years ago. The brand saw strong growth this year supported by preference for natural beverages which offer nutrition in addition to quenching thirst. The Mausambi juice variant which was launched last year received a good response and gained saliency in the portfolio. Retail Business NewU: Dabur operates in the specialized beauty retail business with its wholly-owned subsidiary, H&B Stores Ltd. This is a chain of beauty retail stores under the brand NewU, offering a wide range of beauty care products covering cosmetics,

fragrances, skin care, personal care and beauty and fashion accessories. NewU is today amongst the largest one-stop shop for all beauty care needs with a range of domestic and exclusive international brands available at its stores. Outlook: The FMCG industry in India faced stress at the beginning of the fiscal year due to the implementation of GST but recovered considerably in the later part of the year. That said, implementation of GST in India is a big positive for the FMCG sector as it has enabled a unified tax structure, easier movement of goods across the country, conversion from unorganized to organized sector and streamlining of tax structure across categories. While there are some near-term inflationary pressures and challenges due to the increase in prices of crude oil and other raw materials, overall consumer demand is resilient and the consumer industry is expected to grow at a good pace in the medium to long term. Increasing preference for natural products, rising incomes and aspirations, low penetration of most of the categories and changing lifestyle will be the drivers for the FMCG sector. Company, with its brands, infrastructure, capabilities and management depth is well placed to leverage this opportunity. The Company has a strong product pipeline and has also been aggressively investing in various communication and distribution initiatives to create and efficiently service demand for its products. International markets witnessed recovery after the slowdown on the back of low crude prices in the past few years. Adverse currency movements in some markets like Egypt, Nigeria and Turkey impacted the company s consolidated sales growth although these markets have grown well in local currency terms. The translation impact is likely to reduce in fiscal 2018-19 as the currency depreciation has come into the base. Outlook for African markets remains positive. SAARC region has been stable and performed well. The outlook for this region remains positive for the next fiscal.

Disclosure Section The information and opinions in Firstcall Research was prepared by our analysts and it does not constitute an offer or solicitation for the purchase or sale of any financial instrument including any companies scrips or this is not an official confirmation of any transaction. The information contained herein is from publicly available secondary sources and data or other secondary sources believed to be reliable but we do not represent that it is accurate or complete and it should not be relied on as such. Firstcall Research or any of its affiliates shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Firstcall Research and/ or its affiliates and/or employees will not be liable for the recipients investment decision based on this document. Analyst Certification The following analysts hereby state that their views about the companies and sectors are on best effort basis to the best of their knowledge. Unless otherwise stated, the individuals listed on the cover page of this report are research analysts. The analyst qualifications, sectors covered and their exposure if any are tabulated hereunder: Name of the Analyst Qualifications Sectors Covered Dr.C.V.S.L. Kameswari M.Sc, PGDCA, Pharma & M.B.A, Diversified Ph.D (Finance) U. Janaki Rao M.B.A Capital Goods B. Anil Kumar M.B.A Auto, IT & FMCG Exposure/Interest to company/sector Under Coverage in the Current Report No Interest/ Exposure No Interest/ Exposure No Interest/ Exposure V. Harini Priya M.B.A Diversified No Interest/ Exposure Important Disclosures on Subject Companies In the next 3 months, neither Firstcall Research nor the Entity expects to receive or intends to seek compensation for any services from the company under the current analytical research coverage. Within the last 12 months, Firstcall Research has not received any compensation for its products and services from the company under the current coverage. Within the last 12 months, Firstcall Research has not provided or is providing any services to, or has any client relationship with, the company under current research coverage. Within the last 12 months, Firstcall Research has neither provided or is providing any services to and/or in the past has not entered into an agreement to provide services or does not have a client relationship with the company under the research coverage. Certain disclosures listed above are also for compliance with applicable regulations in various jurisdictions. Firstcall Research does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, No-Weight and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all weights used in Firstcall Research. In addition, since Firstcall Research contains more complete information concerning the analyst's views, investors should carefully read Firstcall Research, in its entirety, and not infer the contents from the weightages assigned alone. In any case, weightages (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell should depend on individual circumstances (such as the investor's own discretion, his ability of understanding the dynamics, existing holdings) and other considerations.

Analyst Stock Weights Overweight (O): The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Equal-weight (E): The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. No-weight (NR): Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Underweight (U): The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months. Unless otherwise specified, the weights included in Firstcall Research does not indicate any price targets. The statistical summaries of Firstcall Research will only indicate the direction of the industry perception of the analyst and the interpretations of analysts should be seen as statistical summaries of financial data of the companies with perceived industry direction in terms of weights. Firstcall Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Firstcall Research. The reports of Firstcall Research are for Information purposes only and is not to be construed as a recommendation or a solicitation to trade in any securities/instruments. Firstcall Research is not a brokerage and does not execute transactions for clients in the securities/instruments. Firstcall Research - Overall Statement S. No Particulars Remarks 1 Comments on general trends in the securities market 2 Discussion is broad based and also broad based indices 3 Commentaries on economic, political or market conditions 4 Periodic reports or other communications not for public appearance 5 The reports are statistical summaries of financial data of the companies as and where applicable 6 Analysis relating to the sector concerned 7 No material is for public appearance 8 We are no intermediaries for anyone and neither our entity nor our analysts have any interests in the reports 9 Our reports are password protected and contain all the required applicable disclosures 10 Analysts as per the policy of the company are not entitled to take positions either for trading or long term in the analytical view that they form as a part of their work 11 12 13 No conflict of interest and analysts are expected to maintain strict adherence to the company rules and regulations. As a matter of policy no analyst will be allowed to do personal trading or deal and even if they do so they have to disclose the same to the company and take prior approval of the company Our entity or any analyst shall not provide any promise or assurance of any favorable outcome based on their reports on industry, company or sector or group

14 Researchers maintain arms length/ Chinese wall distance from other employees of the entity 15 No analyst will be allowed to cover or do any research where he has financial interest 16 Our entity does not do any reports upon receiving any compensation from any company Firstcall Research Provides Industry Research on all the Sectors and Equity Research on Major Companies forming part of Listed and Unlisted Segments For Further Details Contact: Mobile No: 09959010555 E-mail: info@firstobjectindia.com info@firstcallresearch.com www.firstcallresearch.com